Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. Coli nitroreductase and CB1954

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1061-1069

  McNeish, I A ^a   Green, N K ^a   Gilligan, M G ^a   Ford, M J ^b   Mautner, V ^a   Young, L S ^a   Kerr, D J ^a   Searle, P F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CB1954; Nitroreductase; Ovarian cancer; Pancreatic cancer; VDEPT

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; CISPLATIN; NITROREDUCTASE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RETROVIRUS; TARGET CELL; TUMOR CELL LINE;

ANIMALIA; ESCHERICHIA COLI; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0031694118     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300744     Document Type: Article

References (30)

1. Huber B, Richards C, Austin E. Virus-directed enzyme prodrug therapy (VDEPT). Ann NY Acad Sci 1994; 716: 104-114.
2. Huber B et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene - significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302-8306.
3. Freeman S et al. The bystander effect: tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
4. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
5. Austin E, Huber B. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993; 43: 380-387.
6. Mullen C, Kilstrup M, Blaese R. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorourocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
7. Tubiana M, Malaise E. Growth rate and cells kinetics in human tumours: some prognostic and therapeutic implications. In: Symington T, Carter R (eds). Scientific Foundations of Oncology. Heinnemann: London, 1976, pp 126-136.
8. Cobb L et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochem Pharmacol 1969; 18: 1519-1527.
9. Knox R et al. A new cytotoxic, DNA intersrrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridm-1-yl)-2,4-dinitrobenzamide (CB1954) by a nitroreductase enzyme Walker carcinoma cells. Biochem Pharmacol 1988; 37: 4661-4669.
10. Knox R et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5(aziridinyl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988; 37: 4671-4677.
11. Bridgewater J et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370.
12. Boland M, Knox R, Roberts J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB1954 (5-(aziridin-1yl)-2,4-dinitrobenzamide). Biochem Pharmacol 1991; 41: 867-875.
13. Chen S et al. Molecular basis of the catalytic differences among DT-diaphorase of human, rat and mouse. J Biol Chem 1997; 272: 1437-1439.
14. Roberts J, Friedlos F, Knox R. CB1954 (2,4-dinitro-5-azirinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun 1986; 140: 1073-1078.
15. Michael N et al. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its overexpression in Escherichia coli K12. FEMS Microbiol Lett 1994; 124: 195-202.
16. Knox R et al. The bioactivation of CB1954. II: A comparison on an E. coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992; 44: 2297-2301.
17. Anlezark G et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992; 44: 2289-2295.
18. Green N et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-238.
19. Friedlos F et al. Gene-directed enzyme prodrug therapy: quantitative bystander toxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Therapy 1998; 5: 105-112.
20. Clark A et al. Selective cell ablation in transgenic mice expressing E. coli nitroreductase. Gene Therapy 1997; 4: 101-110.
21. Bowles N et al. A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther 1996; 7: 1735-1742.
22. Rea D, Poole C. Chemotherapy for epitheial ovarian cancer: an update. Curr Obstet Gynecol 1997; 7: 50-60.
23. Eliopoulos A et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-1228.
24. Friedlos F et al. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem 1997; 40: 1270-1275.
25. Bailey S et al. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Gene Therapy 1996; 3: 1143-1150.
26. Drabek D et al. The expression of bacterial nitroreductase m transgenic mice results in specific cell killing by the prodrug CB1954. Gene Therapy 1997; 4: 93-100.
27. Markowitz D., Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
28. Cosset F-L et al. High titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
29. Soneoka Y et al A transient three plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J/ Immunol Meth 1983; 65: 1735-1742.